Biogen Idec Earnings Newsletter
-
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
14 May 2025 11:30 GMT
- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first …
-
Otonomy's (OTIC) CEO David Weber on Q4 2019 Results - Earnings Call Transcript
28 Feb 2020 03:01 GMT
… Inc. (NASDAQ:OTIC) Q4 2019 Earnings Conference Call February 27, 2020 … Q4 2019 Otonomy, Inc. Earnings Conference Call. At this time … in today's earnings release and 10-K filing … multiple development programs while at Biogen Idec. Ciara’s experience in drug …